Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ERK phosphorylation predicts synergism between gemcitabine and the epidermal growth factor receptor inhibitor AG1478.

Lung cancer (Amsterdam, Netherlands) - 1 Sept 2011

Luk Peter P, Galettis Peter, Links Matthew

Abstract excerpt

BACKGROUND: Clinical trials combining epidermal growth factor receptor (EGFR) inhibitors with gemcitabine-based chemotherapy in non-small cell lung cancer (NSCLC) have not produced a survival advantage. This may be caused by antagonism between the two drugs or mutations that promote such, possibly RAS mutation. Furthermore, ERK, a critical growth regulator downstream of RAS, may play a role. This study aimed to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Butadienes
Share to Deoxycytidine
Share to Drug Synergism

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Extracellular Signal-Regulated MAP Kinases

Share to Gemcitabine

Share to Nitriles

Share to Quinazolines

Share to Tyrphostins

Source

Identifiers

PMID: 21277645
DOI: 10.1016/j.lungcan.2010.12.016

Genes

KRAS
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ERK phosphorylation predicts synergism between gemcitabine and the epidermal growth factor receptor inhibitor AG1478.PMID 21277645Read ↗

Schedule-dependent synergistic interaction between docetaxel and gefitinib in NSCLC cell lines regardless of the mutation status of EGFR and KRAS and its molecular mechanisms.Semantic proximity Read ↗

Synergistic antitumor efficacy of sequentially combined paclitaxel with sorafenib in vitro and in vivo NSCLC models harboring KRAS or BRAF mutations.Semantic proximity Read ↗

Synergistic inhibition of ErbB signaling by combined treatment with seliciclib and ErbB-targeting agents.Semantic proximity Read ↗

Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells.Semantic proximity Read ↗

Synergistic inhibitory effects by the combination of gefitinib and genistein on NSCLC with acquired drug-resistance in vitro and in vivo.Semantic proximity Read ↗

Synergistic cell growth inhibition by the combination of amrubicin and Akt-suppressing agents in K-ras mutation-harboring lung adenocarcinoma cells: implication of EGFR tyrosine kinase inhibitors.Semantic proximity Read ↗

Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation.Semantic proximity Read ↗

AKT inhibition synergistically enhances growth-inhibitory effects of gefitinib and increases apoptosis in non-small cell lung cancer cell lines.Semantic proximity Read ↗

A novel strategy of EGFR‑TKI combined chemotherapy in the treatment of human lung cancer with EGFR‑sensitive mutation.Semantic proximity Read ↗

Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation.Semantic proximity Read ↗

[Growth inhibition of combined pathway inhibitors on KRAS mutated non-small cell lung cancer cell line].Semantic proximity Read ↗

Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.